-
1 Comment
Replimune Group, Inc is currently in a long term uptrend where the price is trading 6.1% above its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
Replimune Group, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has dropped by 34.6% to $-22M since the same quarter in the previous year.
Finally, its free cash flow grew by 31.2% to $-14M since the same quarter in the previous year.
Based on the above factors, Replimune Group, Inc gets an overall score of 3/5.
Sector | Healthcare |
---|---|
Industry | Biotechnology |
ISIN | US76029N1063 |
CurrencyCode | EUR |
Exchange | F |
Beta | 1.86 |
---|---|
Dividend Yield | 0.0% |
Target Price | 55.22 |
PE Ratio | None |
Market Cap | 1B |
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 7R8.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2024